OptimizeRx Corp. (NASDAQ:OPRX) Stock Has Average Price Target of $11.43

OptimizeRx Corp. (NASDAQ:OPRX) has been given a consensus rating of “Moderate Buy” by the nine ratings firms that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation and six have given a buy recommendation to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $11.43.

Several equities research analysts have recently issued reports on the stock. Citizens Jmp raised their price objective on shares of OptimizeRx from $9.00 to $11.00 and gave the stock a “market outperform” rating in a research note on Friday, August 14th. UBS Group set a $11.00 price target on shares of OptimizeRx in a report on Friday, August 14th. Stifel Nicolaus set a $12.00 price objective on shares of OptimizeRx in a report on Thursday, August 13th. Wall Street Zen lowered shares of OptimizeRx from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 20th. Finally, Citigroup reaffirmed a “market outperform” rating on shares of OptimizeRx in a report on Friday, August 14th.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of OPRX. Royce & Associates LP lifted its position in OptimizeRx by 0.7% in the fourth quarter. Royce & Associates LP now owns 682,030 shares of the company’s stock worth $8,362,000 after purchasing an additional 4,700 shares during the period. Rice Hall James & Associates LLC increased its holdings in OptimizeRx by 1.9% in the 1st quarter. Rice Hall James & Associates LLC now owns 601,921 shares of the company’s stock valued at $3,780,000 after buying an additional 11,247 shares during the period. Dimensional Fund Advisors LP raised its stake in shares of OptimizeRx by 22.3% in the 1st quarter. Dimensional Fund Advisors LP now owns 563,570 shares of the company’s stock valued at $3,540,000 after buying an additional 102,661 shares in the last quarter. Next Century Growth Investors LLC raised its stake in shares of OptimizeRx by 139.8% in the 4th quarter. Next Century Growth Investors LLC now owns 505,407 shares of the company’s stock valued at $6,196,000 after buying an additional 294,688 shares in the last quarter. Finally, AWM Investment Company Inc. bought a new position in shares of OptimizeRx during the 2nd quarter worth about $1,375,000. 76.47% of the stock is currently owned by institutional investors and hedge funds.

OptimizeRx Price Performance

Shares of NASDAQ:OPRX opened at $8.04 on Friday. The business has a 50 day moving average price of $7.37 and a 200 day moving average price of $6.45. OptimizeRx has a twelve month low of $4.54 and a twelve month high of $22.25. The company has a market cap of $151.44 million, a price-to-earnings ratio of 34.96 and a beta of 1.09. The company has a quick ratio of 5.58, a current ratio of 5.58 and a debt-to-equity ratio of 0.14.

OptimizeRx (NASDAQ:OPRX) last released its earnings results on Wednesday, August 12th. The company reported $0.16 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.11 by $0.05. OptimizeRx had a return on equity of 9.44% and a net margin of 4.66%.The firm had revenue of $20.50 million for the quarter, compared to analyst estimates of $20.20 million. Research analysts predict that OptimizeRx will post 0.51 earnings per share for the current year.

OptimizeRx Company Profile

OptimizeRx Corporation (NASDAQ: OPRX) is a digital health company that provides technology and data-driven engagement solutions for life sciences companies, healthcare providers and patients. Its platform is designed to support communication across the healthcare journey, helping pharmaceutical and biotechnology companies connect with clinicians and patients through digital channels.

The company’s solutions include point-of-care messaging, patient savings and financial assistance programs, medication adherence and support services, and analytics and audience-engagement tools.